Drug target Mendelian randomization supports apolipoprotein C3-lowering for lipoprotein-lipid levels reductions and cardiovascular diseases prevention
Éloi Gagnon, Benoît J. Arsenault
Topics & Concepts
Mendelian randomizationMedicineInternal medicineOdds ratioApolipoprotein BSingle-nucleotide polymorphismEndocrinologyGenome-wide association studyCholesterolBioinformaticsGeneticsBiologyGenotypeGeneGenetic variantsLipid metabolism and disordersLipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins